The discovery of recurrent mutations in Janus kinase 2 (JAK2), calreticulin (CALR), and myeloproliferative leukemia oncogene (MPL) as driver mutations has transformed the diagnostic approach of MPN, as evident in the revisions of WHO classifications [1,8,9]. The gene discussed is JAK2; the disease is myeloproliferative disorder.